BioSpace News Archive

Celerion, the leader in early clinical development, is pleased to announce a new core capability for this growing market: the integration of ClinQuick, Celerion’s proprietary electronic data acquisition system, with TrialMaster, OmniComm’s electronic data capture solution, to provide a fully automated clinical trial data management platform.

As per a new World Bank/IFC-funded study by MobileODT and Apollo Hospitals, deploying the EVA System at primary cervical cancer screenings leads to a higher detection rate of suspected precancerous and cancerous lesions for women in both urban and rural areas, than a pap smear alone.

Endari was approved by the FDA to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

Joining the Board of Directors are Betsy D. Holden and Leslie F. Varon, in addition to Don M. Casey Jr., Dentsply Sirona’s newly appointed Chief Executive Officer.

Healthcare 3D printing market projected to reach $2.2B by 2024, driven by applications in tissue engineering and regenerative medicine; Company prepares to take investments for its pioneering 3D bioprinting technology.

MDxHealth today announced that, that it received the following notification of significant shareholdings, in conformity with Article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market.

Orchard Therapeutics today announced the appointment of Frank Thomas to the newly created position of CFO and CBO.

The study used a new molecular genetics method that enables the clear differentiation of human microbial faecal pollution from that of animal origin.

Clinigen today provides a trading update for the six months ended 31 December 2017.

The funding and in-kind services provided by the NEPDC will support development of PathMaker’s MyoAmplifier system, an advanced non-invasive platform that treats patients with paralysis and muscle weakness.